U.S. Patient and Trademark Office, U.S. DEPARTM Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10539390			
Filing Date		2005-06-15			
First Named Inventor	Martin	nus W. BLUM			
Art Unit		2627			
Examiner Name MUH/		AMMAD N. EDUN			
Attorney Docket Number		NI 021317			

					U.S.	PATENTS		Remove			
Examiner Initial*	Cite No Patent Number		Kind Code ¹ Issue Date		Date	Name of Pate of cited Docu	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wis	h to a	i dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant Relev		es,Columns,Lines where evant Passages or Relevant ires Appear		
	1	20020044767	A1	2002-04-18		KWAK					
If you wis	h to a	dd additional U.S. Publ				n information p		d button	Add		
Examiner Cite Foreign Document Country Kind			Publication	Name of Patente Applicant of cited Document	or '	vhere Re	or Relevant				
	1	2001036859	JP		A	2001-02-09	NEC CORP				С
	2	1205929	05929 EP A1		A1	2002-05-15	SHARP KK JP				Г
	3	0193262	wo		A2	2001-12-06	DATAPLAY INC				С

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10539390		
Filing Date		2005-06-15		
First Named Inventor	Martinus W. BLUM			
Art Unit		2627		
Examiner Name	MUHA	AMMAD N. EDUN		
Attorney Docket Numb	er	NL021317		

	4	02052558	wo	A2	2002-07-04	PIONEER CORP				
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
	NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item initials* No bubbles, city and a serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andior country where published.							T6		
	1 STANDARD ECMA 267; 120 mm DVD - Read-Only Disk, Section 4. April 2001									
	2 ISR Publication, International Publication Number WC0004/057600A1									
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE										
Examiner	Examiner Signature Date Considered									
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with payt communication to applicant									

See Kind Code of USPTO Petert Documents at time (USPTO,GG) or MPEP 96164. Teters dots that issued the document, by the involvance on (WPO) Standard ST3.) For Suppresse patient counters, the indication of the parent of the input of the Emperor may preced the serial insulative of the patient document.

Nort of Counters by the appropriate symbols as indicated on the document under WIPO Standard ST3. 16 if possible. **Applicant is to place a check mark here it registed insulations stated.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10539390				
Filing Date		2005-06-15				
First Named Inventor Martin		nus W. BLUM				
Art Unit		2627				
Examiner Name	MUHA	AMMAD N. EDUN				
Attorney Docket Numb	er	NL021317				

CERTIFICATION STATEMENT

Diagon con	37	CER	1 97	and	1 02 6	maka	the	appropriate	coloction	v(e)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- __ N--

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael E. Belk/	Date (YYYY-MM-DD)	2007-07-24
Name/Print	Michael E. Belk	Registration Number	33,357

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.